Russia to increase production of anti-Rhesus immunoglobulin drugs

Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent.

According to some recent Russian media reports, the supplies of anti-Rhesus immunoglobulin drugs to Russia in 2024 fell sharply due to a shortage of raw materials and rising production costs, which posed a threat of its shortage in the local market.

Recently two of the four largest suppliers of the drug to the Russian market reported about the lack of supplies in the first half of the current year.